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PreviewsPPARa: Savior or savage?
The nuclear receptor PPARa is activated by drugs used to decrease heart disease risk by improving circulating lipids. New
findings indicate that PPARa may decrease vascular disease by promoting the activity of a tumor suppressor in smooth
muscle cells, a surprising mechanism since PPARa causes tumors in rodents.Peroxisome proliferator-activated recep-
tors (PPARs) belong to the nuclear re-
ceptor superfamily. In response to ligand
binding, PPARs form a heterodimer with
the retinoid X receptor (RXR) and transac-
tivate genes containing a PPAR response
element (PPRE) (Mangelsdorf et al.,
1995). There are at least three types,
PPARa, PPARg, and PPARd. Since the
initial description of PPARa in 1990 (Isse-
mann and Green, 1990), this class of
nuclear receptors has proved to be an
attractive target for biologists interested
in fatty-acid metabolism, dyslipidemia,
atherosclerosis, chronic inflammation,
and cancer.
PPARa is predominantly expressed in
liver where it plays a critical role in lipid
metabolism by regulating the transport
and catabolism of fatty acids (Figure 1).
The receptor is activated by lipids (Chak-
ravarthy et al., 2005) and by a class of
drugs called fibrates. Agents in this class
(gemfibrozil and fenofibrate in the United
States) are used to lower levels of circu-
lating triglycerides in people at risk for
pancreatitis and to elevate HDL-choles-
terol in people at risk for heart disease,
practices that began long before their
mechanism of action was known. In ad-
dition to liver, PPARa is also expressed
at lower levels in a variety of cell types in-
cluding smooth muscle cells, endothelial
cells, and macrophages, central partici-
pants in processes such as atherosclero-
sis and inflammation.
A new study published in the Journal of
Clinical Investigation shows that PPARa
may affect vascular disease by interfer-
ing with cell-cycle progression in smooth
muscle cells (Gizard et al., 2005). Smooth
muscle cells can contribute to vascular
dysfunction in at least two important
ways. First, they proliferate in response
to percutaneous interventions such as
those involving stent placement. Their
accumulation and secretion of extracel-
lular matrix contributes to restenosis, an
important clinical problem. Second, the
migration of smooth muscle cells into
the neointima coupled with altered phe-
notypic characteristics promotes theCELL METABOLISM : DECEMBER 2005 $ VOLdevelopment of native atherosclerotic
lesions. The new findings suggest that
modulation of PPARa could impact re-
stenosis and perhaps the progression
of common atherosclerotic lesions by al-
tering expression of a cyclin-dependent
kinase inhibitor.
Cyclin-dependent kinase inhibitors are
important regulators of the cell cycle.
They modulate the activity of cyclin-
dependent kinases (CDKs), a family of
highly conserved protein kinases that
phosphorylate multiple proteins regulat-
ing separate phases of cell-cycle pro-
gression (Pietenpol and Kastan, 2004).
One particularly important CDK target
is the retinoblastoma protein (pRB).
Phosphorylation of pRB by the cyclin
D-CDK4 complex promotes cell prolifer-
ation by allowing progression beyond
the G1/S transition of interphase. Con-
versely, whenpRB is less phosphorylated,
cell-cycle progression is decreased.
Gizard and colleagues focused on
p16INK4a (p16), a cyclin-dependent ki-
nase inhibitor and tumor suppressor.
They demonstrated that PPARa activa-
tion induces p16 transcription probably
by interacting with a degenerated PPRE
andSP1sites in the p16promoter. PPARa
was shown to inhibit smooth muscle cell
growth by augmenting p16 expression,
an effect that was amplified by PPARa
agonists and, in the setting of PPARa
overexpression, achieved using an ade-
novirus. PPARa induction of p16 caused
G1 cell-cycle arrest by preventing CDK4
from phosphorylating pRB. Both PPARa-
deficient and p16-deficient cells in
culture had higher proliferation rates
compared to control cells and neither re-
sponded to PPARa agonists by decreas-
ing proliferation. Mechanical injury of the
carotid artery in mice resulted in greater
neointimal formation in PPARa-deficient
as compared to wild-type mice. Greater
lesions were also seen in p16-deficient
mice as compared to control mice. Treat-
ment with the PPARa agonist fenofibrate
increased vascular p16 expression and
decreased neointimal formation in re-
sponse to mechanical injury as compared. 2 $COPYRIGHT ª 2005 ELSEVIER INC.to control animals. Fenofibrate treatment
of p16-deficient animals had no effect on
lesion formation.
Human clinical trials of fibrates have
generally yielded favorable outcomes,
especially when viewed in terms of car-
diovascular endpoints (Staels and Fru-
chart, 2005). The underlying explanation
is not clear since effects on cardiovascu-
lar event rates in fibrate-treated patients
cannot be consistently attributed to ob-
served changes in circulating lipid levels.
In fact, fibrates appear to have beneficial
vascular effects despite possessing cer-
tain proatherogenic properties. Many pa-
tients with elevated triglycerides who are
treated with fibrates show increased lev-
els of LDL cholesterol, a robust mediator
of vascular disease. PPARa agonists in-
crease levels of homocysteine, another
known cardiovascular risk factor (West-
phal et al., 2001). By elegantly establish-
ing a novel molecular link between
PPARa and cell-cycle progression in
smooth muscle cells, a cell type directly
relevant to atherosclerosis, Gizard and
colleagues may have provided a glimpse
into the mechanisms responsible for the
apparently beneficial effects of fibrates
on coronary artery disease. The work
also suggests that PPARa agonists could
decrease restenosis, a problem that per-
sists despite improved outcomes associ-
ated with the use of stents coated with
drugs like rapamycin.
There is a piquant irony associated
with the observation that PPARa activa-
tion induces a tumor suppressor in
smooth muscle cells. In rodents, peroxi-
some proliferators like fibrates cause
tumors, and this effect is mediated by
PPARa. Curiously, PPARa-dependent
pathways have been suggested to in-
crease hepatic expression of cell-cycle
regulatory proteins including CDK4 that
promote cell proliferation (Peters et al.,
1998), the opposite of the effect reported
byGizard and colleagues in smoothmus-
cle cells. Most scientists consider cancer
to be an unlikely clinical side effect of
PPARa activation because of species dif-
ferences between rodents and humans.341
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Figure 1. An unexpected process mediated by PPARa
Activation of the nuclear receptor PPARa by fibrate drugs is known to improve systemic lipid metabolism
through events occurring predominantly in the liver. Activation of hepatic PPARa can also cause peroxisomal
proliferation, liver dysfunction, and tumors (especially in rodents). Recent findings by Gizard and colleagues
show that activation of PPARa in vascular smooth muscle cells surprisingly induces the tumor suppressor
p16 and decreases smooth muscle proliferation, suggesting a potentially novel strategy for treating restenosis
and atherosclerosis.However, the use of clofibrate (a PPARa
agonist no longer available in the United
States) was associated with increased
total mortality due in part to an increased
rate of cancer (Committee of Principal
Investigators, 1984).
So is PPARa a savior or a savage? It
can probably be both, depending on the
degree and site of activation. PPARs are
versatile proteins with effects that
depend on ligand kinetics, the stoichiom-
etry of available coactivators, and com-
petition with other factors such as re-
pressors. The pleiotropic effects of
PPARa could help explain why a recentCollecting new target
Transcriptional regulation is crucial in the
families. Work from Fukui and colleagues
Cell Metabolism identifies a target of the
tion and b cell proliferation.
Although maturity onset diabetes of the
young, or MODY, comprises only a small
proportion of all patients with diabetes, it
342large fenofibrate clinical trial, the Fenofi-
brate Intervention and Event Lowering in
Diabetes (FIELD) study, yielded mixed
benefits (http://www.americanheart.org/
presenter.jhtml?identifier=3035469). By
defining a role for PPARa in the control
of smoothmuscle cell-cycle progression,
Gizard and colleagues have extended
our understanding of the complex events
mediated by this nuclear receptor. Their
findings also raise the possibility that lo-
cal delivery of PPARa activators to sites
of vascular disease could be an ideal
way to save tissues at risk for vasculars in MODY
function of the pancreatic b cell and diabe
(Fukui et al., 2005) and Akpinar and colleag
MODY3 transcription factor HNF-1a that a
has been extremely useful in elucidating
the genetic causes and molecular etiol-
ogy of diabetes. MODY was originallydisease without savaging other tissues
like the liver.
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